Pre-exposure prophylaxis for sexually-acquired HIV risk management: a review
Open Access
- 1 April 2015
- journal article
- review article
- Published by Informa UK Limited in HIV/AIDS - Research and Palliative Care
- Vol. ume 7, 125-136
- https://doi.org/10.2147/hiv.s50025
Abstract
Despite significant efforts, the rate of new HIV infections worldwide remains unacceptably high, highlighting the need for new HIV prevention strategies. HIV pre-exposure prophylaxis (PrEP) is a new approach that involves the ongoing use of antiretroviral medications by HIV-negative individuals to reduce the risk of HIV infection. The use of daily tenofovir/emtricitabine as oral PrEP was found to be effective in multiple placebo-controlled clinical trials and approved by the United States Food and Drug Administration. In addition, the Centers for Disease Control and Prevention in the United States and the World Health Organization have both released guidelines recommending the offer of oral PrEP to high-risk populations. The scale-up of PrEP is underway, but several implementation questions remain unanswered. Demonstration projects and open-label extensions of placebo-controlled trials are ongoing and hope to contribute to our understanding of PrEP use and delivery outside the randomized controlled trial setting. Evidence is beginning to emerge from these open-label studies and will be critical for guiding PrEP scale-up. Outside of such studies, PrEP uptake has been slow and several client- and provider-related barriers are limiting uptake. Maximizing the public health impact of PrEP will require rollout to be combined with interventions to promote uptake, support adherence, and prevent increases in risk behavior. Additional PrEP strategies are currently under investigation in placebo-controlled clinical trials and may be available in the future.Keywords
This publication has 84 references indexed in Scilit:
- Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort studyThe Lancet Infectious Diseases, 2014
- HIV Providers’ Perceived Barriers and Facilitators to Implementing Pre-exposure Prophylaxis in Care Settings: A Qualitative StudyAIDS and Behavior, 2014
- Renal Function of Participants in the Bangkok Tenofovir Study--Thailand, 2005-2012Clinical Infectious Diseases, 2014
- PrEP Awareness and Perceived Barriers Among Single Young Men who have Sex with MenCurrent HIV Research, 2014
- Daily Oral Emtricitabine/Tenofovir Preexposure Prophylaxis and Herpes Simplex Virus Type 2 among Men Who Have Sex with MenPLOS ONE, 2014
- HIV pre-exposure prophylaxis and treatment as prevention: a review of awareness and acceptability among men who have sex with men in the Asia-Pacific region and the AmericasSexual Health, 2014
- How Acceptable are Antiretrovirals for the Prevention of Sexually Transmitted HIV?: A Review of Research on the Acceptability of Oral Pre-exposure Prophylaxis and Treatment as PreventionAIDS and Behavior, 2013
- Are Thai MSM Willing to Take PrEP for HIV Prevention? An Analysis of Attitudes, Preferences and AcceptancePLOS ONE, 2013
- Engaging healthcare providers to implement HIV pre-exposure prophylaxisCurrent Opinion in HIV and AIDS, 2012
- Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in womenThe Lancet, 2011